Cancer as a Therapeutic Agent?

Mario Gosalvez

Laboratorío y Servicío de Bioquímica Experimental(1970-2010), Clínica and Hospital Universitario Puerta de Hierro Madrid and Majadahonda, Comunidad de Madrid, Spain.

DOI: 10.4236/jct.2013.48161                

Abstract

The author, concisely and generically, proposes experimental testing on suitable laboratory animals, in state-of-the-art international centers endowed with cancer reversal experimental techniques. Using mild carcinogens to induce more or less benign growths can be reversed back to a normal state by single or dual strategy: in spinal paralysis by medullar contusion in young rabbits; for blindness caused by the severing of the optic nerve in sheep; for neural deafness caused by severing the acoustic nerve in rabbits. If these techniques could be shown to be feasible and successful for higher order primates and if having then already cured for life a sufficient number of malignant cancers by cancer reversal by dual strategy in human beings, of course these methods could be then considered for patients.

Keywords

Mild Carcinogenesis and Cancer Reversal; Animal Recoveries from Spinal Paralysis; Blindness and Deafness; Mitochondrial Filamentation

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. Gosalvez, “Oxygen Production by Filament Mitochondria. Importance in Cancer and Neurodegeneration,” Anales de la Real Academia Nacional de Medicina (Madrid) Spain, Vol. 115, No. 3, 1998, pp. 747-756.
[2]	M. Gosalvez, “Reversion of Cancer and Mitochondrial Filamentation,” Anales de la Real Academia Nacional de Medicina (Madrid) Spain, Vol. 117, No. 4, 2000, pp. 825-834.
[3]	M. Gosalvez and S. Weinhouse, “Control Mechanism of Oxygen and Glucose Utilization in Tumors,” Advances in Experimental Biology and Medicine, Vol. 75, 1976, pp. 587-596. http://dx.doi.org/ 10.1007/978-1-4684-3273-2_69
[4]	M. Gosalvez, “Mitochondrial Filamentation,” 101th AACR Meeting, Washington DC, 17-21 April 2010, pp. 3-7.
[5]	M. Gosalvez, “Reversal of Cancer by Dual Strategy: A New Molecular Target,” 103rd AACR Meeting, Chicago, 31 March-4 April 2012, p. 1118.
[6]	M. Gosalvez, “Mitochondrial Filamentation: Some Methods of Isolation and Assay,” IOSR Journal of Pharmacy and Biological Sciences, Vol. 4, No. 4, 2012, pp. 37-39. http://dx.doi.org/10.9790/3008-0443739
[7]	M. Gosalvez, “Methods to Be Developed for Some First Applications of Mitochondrial Filamentation,” Open Journal of Biophysics, Vol. 3, No. 1A, 2013, pp. 51-53. http://dx.doi.org/10.4236/ojbiphy. 2013.31A006
[8]	M. Gosalvez, “Metabolic Control of Respiration and Glycolysis of Tumoral Cells,” Advances in Biological Chemistry, Vol. 3, No. 1, 2013, pp. 86-89. http://dx.doi.org/10.4236/abc.2013.31011
[9]	M. Gosalvez, “Reversal of Cancer by Dual Strategy?” Journal of Cancer Therapy, Vol. 3, No. 4, 2013, pp. 518-520.
[10]	M. Gosalvez, “Mitochondrial Filamentation: A Therapeutic Target for Neurodegeneration and Aging?” Journal of Alzheimer’s Disease & and Other Dementias, Vol. 28, No. 5, 2013, pp. 423-426. http://dx.doi.org/10.1177/1533317513494451
[11]	L. Lopez-Alarcon, et al., “Quantitative Determination of the Degree of Differentiation of Mammary Tumors by Pyruvate Kinase Analysis,” Cancer Research, Vol. 41, No. 5, 1981, pp. 2019-2020.
[12]	A. Brugarolas and M. Gosalvez, “Preliminary Clinical Results with Norgamen (thioproline) and Revercan (2-Amino-thiazoline): The First Inducers of Reverse Transformation,” Adjuvant Therapies of Cancer, Recent Results in Cancer Research, Vol. 80, 1982, pp. 346-350. http://dx.doi.org/10.1007/978-3-642-81685-7_56
[13]	H. Cortes-Funes, et al., “Quelamycin: A Summary of Phase I Clinical Trials,” Recent Results in Cancer Research, Vol. 74, No. , 1980, pp. 2000-2009. http://dx.doi.org/10.1007/978-3-642-81488-4_25
[14]	M. Gosalvez and A. Brugarolas, “Treatment of Cancer by an Inducer of Reverse Transformation,” The Lancet, Vol. 1, No. 8159, 1980, pp. 68-70.
[15]	M. Gosalvez y Gosalvez, “Basis for Design of Pharmacological Effectors Acting on Plasma Membrane Receptors,” Biochemical Society Transactions, Vol. 1, 1981, pp. 151-152.
[16]	M. Gosalvez, “The Zipper Mechanism,” Comercial Malvar, Madrid, 1982.
[17]	M. Gosalvez, “Carcinogenesis with the Insecticide Rotenone,” Life Sciences, Vol. 32, No. 8, 1983, pp. 809-816. http://dx.doi.org/10.1016/0024-3205(83)90216-3
[18]	M. Gosalvez, “Thioproline and the Reversal of Cancer,” The Lancet, Vol. 1, No. 8333, 1983, p. 1118.
[19]	M. Gosalvez, et al., “Spectral and Metabolic Characteristics of Mitochondrial Fractions Isolated from Rotenone Induced Tumours,” British Journal of Cancer, Vol. 36, No. 2, 1977, pp. 243-252. http://dx.doi.org/10.1038/bjc.1977.184
[20]	M. Gosalvez, et al., “Treatment of Intravenous Leukemia 1210 Transplants with Tumor Modifiers. Redoubt Cytotoxics and Minor Tranquilizers,” Aminoacids Chemistry, Biology and Medicine, Escom Sciences Publishers, Leiden, 1990, pp. 704-711.
[21]	M. Gosalvez, “Cancer Reversal by Dual Strategy,” Editorial Gober, Madrid, 1992.
[22]	M. Gosalvez, “Extension of Metabolic Life. Abstract,” Proceedings of the 36th ISOTT Meeting, Sapporo, 3-7 August 2008, p. 52.